Venturi Wealth Management LLC Boosts Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Venturi Wealth Management LLC grew its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 89.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,382 shares of the company’s stock after purchasing an additional 1,601 shares during the period. Venturi Wealth Management LLC’s holdings in Elanco Animal Health were worth $50,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Atria Investments Inc increased its position in shares of Elanco Animal Health by 57.9% in the third quarter. Atria Investments Inc now owns 56,613 shares of the company’s stock worth $832,000 after purchasing an additional 20,760 shares during the last quarter. Graypoint LLC increased its holdings in shares of Elanco Animal Health by 19.6% in the 3rd quarter. Graypoint LLC now owns 31,989 shares of the company’s stock worth $470,000 after buying an additional 5,250 shares during the last quarter. ASB Consultores LLC raised its position in shares of Elanco Animal Health by 33.9% during the 3rd quarter. ASB Consultores LLC now owns 23,700 shares of the company’s stock valued at $348,000 after buying an additional 6,000 shares in the last quarter. Innealta Capital LLC lifted its holdings in shares of Elanco Animal Health by 78.1% during the 3rd quarter. Innealta Capital LLC now owns 19,981 shares of the company’s stock worth $294,000 after acquiring an additional 8,760 shares during the last quarter. Finally, Harbor Capital Advisors Inc. grew its position in Elanco Animal Health by 101.1% in the third quarter. Harbor Capital Advisors Inc. now owns 874,895 shares of the company’s stock worth $12,852,000 after acquiring an additional 439,757 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Analysts Set New Price Targets

ELAN has been the subject of several research analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and set a $20.00 price target on shares of Elanco Animal Health in a research note on Thursday, September 19th. Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $17.00 to $15.00 in a research note on Thursday, September 19th. Finally, Barclays lifted their price target on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $17.14.

Elanco Animal Health Stock Down 0.4 %

Shares of Elanco Animal Health stock opened at $13.98 on Friday. The company’s 50 day moving average price is $13.82 and its 200-day moving average price is $14.75. Elanco Animal Health Incorporated has a 52-week low of $11.20 and a 52-week high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The stock has a market capitalization of $6.91 billion, a price-to-earnings ratio of 34.95, a P/E/G ratio of 1.48 and a beta of 1.41.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.01. The firm had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.04 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company’s revenue for the quarter was down 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.18 earnings per share. Equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Insider Buying and Selling at Elanco Animal Health

In related news, Director Michael J. Harrington purchased 3,500 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The shares were acquired at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the acquisition, the director now directly owns 81,094 shares in the company, valued at approximately $1,204,245.90. The trade was a 4.51 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.57% of the stock is currently owned by corporate insiders.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.